Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arès To Lead Up Pharmascience In 2023 After Leaving Sandoz

Former Sandoz VP For Biosimilars Replaces Long Serving David Goodman

Executive Summary

Martin Arès is to return to his native Canada early in the new year to take the top job at local generics player Pharmascience, after seven years with Sandoz.

You may also be interested in...



Pharmascience Faces Six-Year Wait On Canadian Invega Sustenna

Pharmascience has failed in a two-pronged validity challenge to a key patent shielding Janssen’s Invega Sustenna treatment for schizophrenia.

Apotex Debuts Eliquis Rival In Canada

Apotex has introduced Canada’s first generic version of Eliquis in the form of its Apo-Apixaban product. The launch comes after the firm was also among a wave of Aubagio teriflunomide generics to hit the Canadian market.

Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued

In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel